Cargando…
Effects of Adjunctive Betahistine Therapy on Lipid Metabolism in Patients with Chronic Schizophrenia: A Randomized Double-Blind Placebo-Controlled Study
OBJECTIVE: This study aims to explore the ability of betahistine to inhibit weight gain and abnormal lipid metabolism in patients with chronic schizophrenia. METHODS: A comparison study of betahistine or placebo therapy was conducted for 4 weeks in 94 patients with chronic schizophrenia, who were ra...
Autores principales: | Bai, Luyuan, Liang, Weiye, Wang, Yongqian, Fan, Ning, zhang, Qi, Bian, Yun, Yang, Fude |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9984272/ https://www.ncbi.nlm.nih.gov/pubmed/36874957 http://dx.doi.org/10.2147/NDT.S392770 |
Ejemplares similares
-
High-Dose Betahistine Improves Cognitive Function in Patients With Schizophrenia: A Randomized Double-Blind Placebo-Controlled Trial
por: Wang, Yongqian, et al.
Publicado: (2021) -
Effects of Betahistine on Vestibulo-Ocular Reflex in Normal Healthy Adults: A Randomized Double-Blind, Placebo-Controlled Trial
por: Wan Hassan, Wan Ahmad Amiruddin, et al.
Publicado: (2022) -
Adjunctive treatment for cognitive impairment in patients with chronic schizophrenia: a double-blind, placebo-controlled study
por: Zhu, Weiwei, et al.
Publicado: (2014) -
Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine
por: Goadsby, Peter J, et al.
Publicado: (2019) -
Effect of probiotics on length of hospitalization in mild acute pancreatitis: A randomized, double-blind, placebo-controlled trial
por: Wan, You-Dong, et al.
Publicado: (2021)